BioSpace News Archive

scPharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved FUROSCIX® (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for the treatment of congestion due to fluid overload in adults with New York Heart Association Class II/III chronic heart failure.

Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report fourth quarter 2022 financial results on Friday, October 14, 2022, premarket.

The ability to optimize precision medicine therapies for patients fighting aggressive and deadly brain cancers like Glioblastoma Multiforme (GBM) starts with quality tissue specimens with molecular integrity intact.

Scientists from The Feinstein Institutes for Medical Research, Kevin J. Tracey, MD, and Valentin Pavlov, PhD, published in Neuron findings of preclinical and clinical research in bioelectronic medicine, highlighting potential hope for patients who live with inflammatory diseases, cancer, diabetes, rheumatoid arthritis and other disorders.

Synergys Biotherapeutics, a preclinical stage biotherapeutics company developing Vasculogenic Mimicry (VM)-blocking antibody fusion drugs, announced today that it has been awarded a Phase I/Phase II Fast-Track grant from the National Cancer Institute under the auspices of the Small Business Innovation Research (SBIR) program of the National Institutes of Health.

The American Association of Clinical Endocrinology (AACE) issued an update to its Developing a Diabetes Mellitus Comprehensive Care Plan guideline, which included a grade A recommendation* for Bayer’s KERENDIA® (finerenone) for the management of patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to improving health equity for seniors, today announced that it will report third quarter 2022 financial results after market close on Monday, November 7, 2022.

Atara Biotherapeutics, Inc. reported the grant of 8,000 restricted stock units of Atara’s common stock to one newly hired employee.

CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2022 after the market close on Wednesday, October 26, 2022.

Crinetics Pharmaceuticals, Inc. announced that on October 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 237,600 shares of its common stock to eleven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.